|
| Press Releases |
|
 |
|
| Tuesday, December 2, 2025 |
|
|
GEN 宣布針對阿茲海默症及其他神經退化性疾病之試驗藥物 SUL-238 取得全新第一期試驗正面數據 |
| 土耳其領先的專業製藥公司GEN Pharmaceuticals（GENIL.IS）今日宣布，其針對首創口服型線粒體靶向藥物候選物 SUL-238 於健康老年志願者中進行的安全性、耐受性及藥代動力學（PK）評估之第一期臨床試驗取得新進展。該研究成果於今日在美國加州聖地牙哥舉行的第 18 屆阿茲海默症臨床試驗大會（CTAD）發表。 more info >> |
|
|
GEN 宣布针对阿尔茨海默病及其他神经退行性疾病的试验性药物 SUL-238 取得新的积极 I 期临床试验数据 |
| 土耳其领先的专科制药公司GEN Pharmaceuticals（GENIL.IS）宣布，其针对首创口服线粒体靶向药物候选物 SUL-238 的安全性、耐受性和药代动力学（PK）的 I 期临床试验在健康老年志愿者中取得新的积极结果。该研究成果于今日在美国加利福尼亚州圣地亚哥举行的第 18 届阿尔茨海默病临床试验大会（CTAD）上公布。 more info >> |
|
|
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases |
| GEN Pharmaceuticals (GENIL.IS), Turkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. more info >> |
|
| Tuesday, July 29, 2025 |
|
|
GEN 與 Sulfateq BV 公佈治療阿茲海默症及其他神經退化性疾病的候選藥物 SUL-238 的第一階段臨床試驗正面結果 |
| GEN製藥公司（GENIL.IS）是土耳其領先的專業製藥公司，日前宣布其第一階段臨床試驗取得積極結果。該試驗旨在評估首創且新型的口服線粒體靶向候選藥物 SUL-238 在健康老年志願者中的安全性、耐受性以及藥代動力學（PK）表現。研究結果已在2025年阿茲海默症協會國際會議（AAIC®）上於多倫多公佈。 more info >> |
|
|
GEN 与 Sulfateq BV 公布治疗阿尔茨海默病及其他神经退行性疾病的候选药物 SUL-238 的第一阶段临床试验积极结果 |
| GEN制药公司（GENIL.IS）是土耳其领先的专业制药公司，日前宣布其第一阶段临床试验取得积极结果。该试验旨在评估首创且新型的口服线粒体靶向候选药物 SUL-238 在健康老年志愿者中的安全性、耐受性以及药代动力学（PK）表现。研究结果已在2025年阿尔茨海默病协会国际会议（AAIC®）上于多伦多公布。 more info >> |
|
| Monday, July 28, 2025 |
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases |
| more info >> |
|
| Wednesday, September 25, 2024 |
|
|
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis |
| GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱重工、新しい経営方針「ITO」の実践による優秀事例を顕彰
Mar 18, 2026 14:00: JST
|
|
|
GUOQUAN FOOD (2517.HK) Surging core operating profit, Four Stores Jointly Advancing with Concerted Efforts for Long-Term Growth
Mar 18, 2026 13:54 HKT/SGT
|
|
|
FILMART and EntertainmentPulse 2026 open today
Mar 18, 2026 14:42 JST
|
|
|
Chuangxin Industries Announces 2025 Annual Results
Mar 18, 2026 09:30 HKT/SGT
|
|
|
創新實業公佈2025年全年業績 收入及利潤穩步增長
Mar 18, 2026 09:00 HKT/SGT
|
|
|
创新实业公布2025年全年业绩 收入及利润稳步增长
Mar 18, 2026 00:04 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 23:05: JST
|
|
|
Maxon、リアルタイム建築ビジュアライゼーションソリューションでAEC市場に正式参入
Mar 17, 2026 23:05: JST
|
|
|
Maxon, 실시간 Archviz 솔루션으로 AEC 시장 공식 진출
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出即時Archviz解決方案，正式進軍AEC市場
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出实时Archviz解决方案，正式进军AEC市场
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 22:05 HKT/SGT
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00: JST
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00 HKT/SGT
|
|
|
Geo Energy's Integrated Infrastructure Project Achieves 80% Completion; Secures Two Binding Term Sheets with Third Parties for 9 Million Tonnes Annual Haulage; Coal Prices Surge Amid Global Tensions
Mar 17, 2026 22:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
